Natera CEO Steven Chapman discusses the uplift in both academic and community settings for Signatera usage. The Nature Medicine paper showcases Signatera's predictive ability for overall survival, and the 702 study will reveal its performance in predicting DFS and OS benefits from Celecoxib.